Patents Assigned to Merck Frosst Canada
  • Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
    Patent number: 7144913
    Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: December 5, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Zhaoyin Wang, Christian Beaulieu, Claude Dufresne, Daniel Guay, Yves LeBlanc
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 7060715
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: June 13, 2006
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
    Patent number: 7019022
    Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: March 28, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Christian Beaulieu, Daniel Guay, Zhaoyin Wang, Robert Zamboni
  • Substituted 8-arylquinolune PDE4 inhibitors
    Patent number: 6919353
    Abstract: 8-arylquinolines of formula (I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, and other diseases. R1-R7 and Ar are as in claim 1.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: July 19, 2005
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Yves Girard, Dwight MacDonald, Anthony Mastracchio, Michel Gallant, Patrick Lacombe, Denis Deschenes
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6841564
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Cathepsin cysteine protease inhibitors
    Patent number: 6835727
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: December 28, 2004
    Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd., Axys Pharmaceuticals, Inc.
    Inventors: Osamu Okamoto, Jean-Pierre Falgueyret, Renata Marcella Oballa, Petpiboon Prasit, Robert Rydzewski
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6812346
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: November 2, 2004
    Assignee: Merck Frosst Canada and Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
  • Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
    Patent number: 6777433
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: August 17, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Robert Young
  • Alkyne-aryl phosphodiesterase-4 inhibitors
    Patent number: 6743802
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: June 1, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    Patent number: 6740666
    Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 25, 2004
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Dwight Macdonald, Helene Perrier, Roch Thibert, Guo-Jie Ho, Anant Vailaya, David Conlon, Elizabeth Kwong, Sophie-Dorothee Clas
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Publication number: 20040029921
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: March 24, 2003
    Publication date: February 12, 2004
    Applicant: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
  • 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
    Patent number: 6677351
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Pyrazinones, compositions containing such compounds and methods of use
    Publication number: 20030236402
    Abstract: Compounds represented by formula I: 1
    Type: Application
    Filed: July 25, 2002
    Publication date: December 25, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Method of treating colonic adenomas
    Patent number: 6649649
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 18, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada, & Co.
    Inventors: Stacia Kargman, Thomas J. Simon, Jilly Evans
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6639077
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 28, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Bernard Cote, Evelyn Martins, Richard Frenette, Rick Friesen, Yves Ducharme
  • Method for treating or preventing emesis
    Patent number: 6610720
    Abstract: Alpha-2 adrenoreceptor agonists are useful for the treatment and/or prevention of emesis in patients.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: August 26, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventor: Annette Robichaud
  • Methods for inhibiting bone resorption
    Patent number: 6586457
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: July 1, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
    Patent number: 6552168
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are caspase-3 inhibitors. The invention also encompasses certain pharmaceutical compositions for treatment of caspase-3 mediated diseases comprising compounds of formula I.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: April 22, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Erich L. Grimm, Johanne Renaud, Renee Aspiotis, Christopher I. Bayly, Robert Zamboni, Shawn Black
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Publication number: 20030065011
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 3, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
    Patent number: RE38103
    Abstract: The Compound of Formula I and pharmaceutically acceptable sales thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: April 29, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Guay, Chun-Sing Li